Clinical Trials Directory

Trials / Completed

CompletedNCT01172288

N-acetylcysteine (NAC) for Children With Tourette Syndrome

Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
8 Years – 17 Years
Healthy volunteers
Not accepted

Summary

Tourette syndrome is a childhood-onset neuropsychiatric disorder characterized by multiple motor and vocal tics that last for at least a year in duration. Currently, there exist several effective pharmacological treatments for childhood tics including alpha-2 agonist medications (guanfacine and clonidine) and neuroleptics (antipsychotic) medications. These medications, however, have significant side-effects and are only partially efficacy in treating tics. N-acetylcysteine (NAC) is a natural supplement that acts as an antioxidant and glutamate modulating agent. NAC has been used safely for decades in doses 20-40 times higher than in this trial as an antidote for acetaminophen overdose. The only side-effect commonly seen with NAC is nausea and this side-effect is seldom seen in the doses used in this trial. NAC has recently been demonstrated to be effective in a double-blind, placebo-controlled trial in adults with trichotillomania (chronic hair pulling). Hairpulling is hypothesized to be closely related to tics because these conditions (1) have similar clinical characteristics -- both groups typically experience urges before engaging in pulling or tics, (2) neuroimaging studies suggest they involve similar brain circuits -- the basal ganglia, (3) the same pharmacological treatments (neuroleptics) may be effective for both conditions and (4) they tend to be inherited together in families. In other trials NAC has evidence of some efficacy in treating diverse psychiatric conditions such as bipolar depression, schizophrenia and cocaine dependence. The investigators are conducting this trial to determine if NAC is an effective treatment for tics.

Conditions

Interventions

TypeNameDescription
DRUGN-Acetylcysteine (NAC)1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
DRUGPlacebo1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.

Timeline

Start date
2010-07-01
Primary completion
2014-01-01
Completion
2014-01-01
First posted
2010-07-29
Last updated
2017-02-10
Results posted
2016-12-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01172288. Inclusion in this directory is not an endorsement.